Home LiteratureArticle Details
PMID: 3324962 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

Antimicrobial agents and chemotherapy ·Vol. 31 ·No. 11 ·1987-11-00 ·Pages 1809-15

Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF

Abstract

The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared. Although there was only a minor difference between the MBCs of both drugs, the bacterial killing rate of ciprofloxacin in vitro was very fast in comparison with that of ceftazidime. Similarly, the intravenous administration of ciprofloxacin at 1 h after bacterial inoculation resulted in effective bacterial killing in the lungs of leukopenic rats. This killing was dose dependent, in contrast to the dose-independent bactericidal effect of ceftazidime. The high antibacterial activity of ciprofloxacin in the lungs as compared with that of ceftazidime was also reflected in its therapeutic efficacy in K. pneumoniae pneumonia and septicemia in leukopenic rats when these infections were treated at 6-h intervals over 4 days, starting at 5 h after bacterial inoculation. Concentrations of ciprofloxacin and ceftazidime in lung tissue were not significantly different. Regarding the antibacterial activity of both drugs against K. pneumoniae in relation to the bacterial growth rate in vitro and in the lungs of leukopenic rats, ciprofloxacin killed K. pneumoniae organisms that were not actively growing, whereas ceftazidime did not. In addition, it was demonstrated that when the intravenous administration of antibiotic was delayed from 1 h up to 24 h after bacterial inoculation, ceftazidime lost its antibacterial activity in the lungs and blood of leukopenic rats, whereas ciprofloxacin was still very effective. These data suggest that the capacity of an antibiotic to kill bacteria at a slow growth rate may be relevant for its therapeutic effect in established infections, in which slowly growing bacteria form a substantial part of the total bacterial population.

MeSH Terms
Animals Ceftazidime/administration & dosage,pharmacokinetics,pharmacology Ciprofloxacin/administration & dosage,pharmacokinetics,pharmacology Drug Administration Schedule Female Klebsiella Infections/drug therapy Klebsiella pneumoniae/drug effects,growth & development Leukopenia/complications,microbiology Lung/microbiology Microbial Sensitivity Tests Pneumonia/drug therapy Rats Sepsis/drug therapy
Chemicals
Ciprofloxacin Ceftazidime
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Roosendaal R
Department of Clinical Microbiology and Antimicrobial Therapy, Erasmus University Rotterdam, The Netherlands.
Bakker-Woudenberg I A
van den Berghe-van Raffe M
Vink-van den Berg J C
Michel M F
References (26)
26 references, click to expand
  1. Simplified, accurate method for antibiotic assay of clinical specimens.
    Appl Microbiol. 1966 Mar;14(2):170-7 PMID: 4959982
  2. Penetration of ciprofloxacin into human lung tissue following intravenous injection.
    Infection. 1986 Nov-Dec;14(6):299-300 PMID: 3818107
  3. Generation times of Proteus mirabilis and Escherichia coli in experimental infections.
    Chemotherapy. 1973;19(3):161-70 PMID: 4587820
  4. Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia.
    Am J Med. 1982 Apr;72(4):561-8 PMID: 7041642
  5. Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.
    Antimicrob Agents Chemother. 1982 Dec;22(6):1042-50 PMID: 6297384
  6. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
    Antimicrob Agents Chemother. 1983 Apr;23(4):559-64 PMID: 6222695
  7. Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy.
    Eur J Cancer Clin Oncol. 1984 Jan;20(1):55-60 PMID: 6537916
  8. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.
    J Infect Dis. 1984 Jun;149(6):980-5 PMID: 6429255
  9. Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
    Antimicrob Agents Chemother. 1984 Jul;26(1):1-4 PMID: 6433786
  10. Pharmacokinetics of intravenously administered ciprofloxacin.
    Antimicrob Agents Chemother. 1984 Aug;26(2):208-10 PMID: 6486762
  11. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    J Infect Dis. 1985 Feb;151(2):291-4 PMID: 3155780
  12. Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.
    Antimicrob Agents Chemother. 1985 Apr;27(4):452-4 PMID: 3159336
  13. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.
    Antimicrob Agents Chemother. 1985 Oct;28(4):524-7 PMID: 2934022
  14. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
    Antimicrob Agents Chemother. 1985 Oct;28(4):581-6 PMID: 3000292
  15. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats.
    Antimicrob Agents Chemother. 1985 Nov;28(5):654-9 PMID: 3911879
  16. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Antimicrob Agents Chemother. 1985 Nov;28(5):716-21 PMID: 2936302
  17. The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat.
    J Infect Dis. 1986 Apr;153(4):707-14 PMID: 2936832
  18. [Mechanism of action of quinolones].
    Infection. 1986;14 Suppl 1:S3-15 PMID: 2420724
  19. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
    Antimicrob Agents Chemother. 1985 Aug;28(2):331-42 PMID: 2939797
  20. Overview of clinical experience with ciprofloxacin.
    Eur J Clin Microbiol. 1986 Apr;5(2):214-9 PMID: 3013631
  21. Clinical experience with ciprofloxacin in the USA.
    Eur J Clin Microbiol. 1986 Apr;5(2):220-5 PMID: 2941286
  22. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
    J Antimicrob Chemother. 1986 May;17(5):641-9 PMID: 2941403
  23. Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat.
    Antimicrob Agents Chemother. 1986 May;29(5):797-802 PMID: 3089141
  24. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats.
    Antimicrob Agents Chemother. 1986 Sep;30(3):403-8 PMID: 3535664
  25. Pharmacokinetics of ciprofloxacin. 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats.
    Arzneimittelforschung. 1986 Oct;36(10):1503-10 PMID: 3101707
  26. The true division and death rates of Salmonella typhimurium in the mouse spleen determined with superinfecting phage P22.
    Br J Exp Pathol. 1968 Dec;49(6):597-613 PMID: 4884387
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1987-11-00
Pages
1809-15
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC175044
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com